It has been well established that HER2 expression is dynamic and that it can change as the disease progresses with up to 40% discordance between primary and metastatic tumors; HER2-low expression appears to be enriched in the advanced setting [15,16]. Here, ERBB2 is linked to metastatic neoplasm.